Privi Speciality Chemicals Ltd. announced the outcome of its Board meeting held on February 9, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Critically, the Board also sanctioned an equity investment of Rs. 50 Crores into its subsidiary, Prigiv Specialties Private Limited, to support future growth plans.
Financial Results for Q3 FY26 Approved
The Board of Directors of Privi Speciality Chemicals Limited convened on Monday, February 09, 2026, and subsequently approved the Unaudited Standalone and Consolidated Financial Results for the period ended December 31, 2025. The results for the quarter and the nine-month period were noted on record.
Key Consolidated Financial Highlights (Unaudited)
The results demonstrate growth compared to the previous year’s corresponding periods.
- Revenue from Operations (Nine Months ended Dec 31, 2025): Rs. 1,84,216.77 Lakhs, compared to Rs. 1,48,764.06 Lakhs in the previous nine months.
- Profit Before Tax (Q3 ended Dec 31, 2025): Rs. 10,377.03 Lakhs.
- Net Profit (Nine Months ended Dec 31, 2025): Attributable to owners of the Holding Company stood at Rs. 23,383.76 Lakhs.
- Earnings Per Share (Basic and Diluted) (Nine Months ended Dec 31, 2025): Rs. 59.86 per share.
Management noted that the financial results reflect the evaluation of the impact of the new consolidated labour codes, resulting in an incremental provision of Rs. 389.96 lakhs towards employee benefit expenses.
Strategic Equity Investment in Subsidiary
The Board also sanctioned a strategic equity infusion into its subsidiary, Prigiv Specialties Private Limited, maintaining the existing 51:49 shareholding ratio.
- Total Investment Amount: Rs. 50 Crores.
- Privi’s Share: Privi Speciality Chemicals Limited will contribute 51%, amounting to Rs. 25.5 Crores.
- JV Partner’s Share: The remaining 49% will be contributed by the Joint Venture Partner, Givaudan SA.
The infusion is intended to support the subsidiary’s growth trajectory, aiming for higher revenue and improved profitability moving forward. Prigiv Specialties Private Limited is primarily engaged in the manufacturing of Chemicals, aligning with the core business of the Parent Company.
Transaction Details (Related Party)
This transaction is classified as a related party transaction. The investment is confirmed to be conducted on an “arm’s length basis”. Mr. Mahesh P Babani (Promoter, CMD) and Ms. Jyoti Mahesh Babani (Promoter) represent the Company on Prigiv’s Board. The total cash consideration for the acquisition of equity shares is approximately Rs. 25,50,00,000/- (Rupees Twenty-Five Crores Fifty Lakh only) at par value.
Source: BSE
